Research shows that damaged cells accumulating in the lungs may explain why obesity and diabetes lead to lung scarring. A 2026 study found that a new drug called MitoTam reduced these damaged cells and prevented lung scarring in obese mice, while weight-loss surgery produced similar cellular improvements in 15 human patients. According to Gram Research analysis, this identifies cellular senescence as a treatable cause of metabolic-related lung disease, though human trials are still needed.
Researchers discovered that a buildup of old, damaged cells in the lungs may be the missing link between obesity, diabetes, and a serious lung disease called pulmonary fibrosis. In a 2026 study, scientists tested a new drug called MitoTam that targets these damaged cells. According to Gram Research analysis, the drug improved blood sugar control, reduced weight, and decreased lung damage in obese mice. The same team also studied people who had weight-loss surgery and found similar improvements in their lung health. These findings suggest that removing these damaged cells could be a new way to treat lung disease in people with metabolic problems.
Key Statistics
A 2026 research article in Aging and Disease found that MitoTam, a mitochondria-targeted drug, markedly decreased senescence markers in the lungs of obese mice while reducing inflammatory and fibrotic gene expression.
In 15 patients with class III obesity, laparoscopic sleeve gastrectomy significantly reduced adipose tissue senescence and pro-fibrotic signaling, including endothelin-1 expression and its circulation levels.
The study identified that senescent cells promote secretion of pro-fibrotic mediators including GDF15, FGF2, TGFβ, and endothelin-1, which impair lung structure and repair in metabolic dysfunction.
MitoTam treatment improved glucose homeostasis, reduced adiposity, and alleviated lung hypoxia in diet-induced obese mice while lowering senescence in both lung and subcutaneous adipose tissue.
The Quick Take
- What they studied: Whether removing old, damaged cells from the body could prevent or treat lung scarring in people with obesity and diabetes
- Who participated: Mice with diet-induced obesity and 15 human patients with severe obesity who underwent weight-loss surgery
- Key finding: A new drug called MitoTam reduced damaged cells in the lungs, decreased inflammation, and prevented lung scarring in obese mice. In humans, weight-loss surgery similarly reduced these damaged cells and improved lung health markers.
- What it means for you: This research suggests a new treatment approach for lung disease in people with obesity or diabetes, though human trials are still needed to confirm safety and effectiveness
The Research Details
This study combined laboratory research with human observations. First, researchers gave obese mice a new drug called MitoTam that targets damaged cells in the body. They measured changes in blood sugar, weight, and lung health. Second, they studied 15 patients with severe obesity who had weight-loss surgery and tracked how their lung health markers changed after surgery. The researchers compared results between the drug-treated mice and the surgery patients to see if both approaches worked similarly.
Understanding why obesity leads to lung disease is important because many people with weight problems develop serious lung scarring. If scientists can identify the exact cause—in this case, damaged cells—they can develop targeted treatments. This approach is better than just treating symptoms because it addresses the root problem.
The study included both animal testing and human data, which strengthens the findings. However, the human sample was small (15 patients), so results need confirmation in larger studies. The research was published in a peer-reviewed journal, meaning other experts reviewed it for accuracy. The findings are recent (2026) and represent cutting-edge science.
What the Results Show
In obese mice treated with MitoTam, researchers observed significant improvements across multiple measures. Blood sugar control improved, body fat decreased, and damaged cells in the lungs dropped dramatically. The drug reduced inflammation and prevented the buildup of scar tissue in lung tissue. Importantly, the mice also showed better oxygen levels in their blood, indicating their lungs were working better. The drug worked by targeting damaged cells in fat tissue as well, suggesting it had effects throughout the entire body, not just in the lungs.
The research identified specific proteins that damaged cells produce, including GDF15, FGF2, TGFβ, and endothelin-1. These proteins appear to trigger lung scarring. When MitoTam reduced damaged cells, these harmful proteins decreased. In the human patients who had weight-loss surgery, the same pattern emerged: body weight dropped substantially, blood sugar improved, and the levels of these pro-scarring proteins decreased in their blood and fat tissue.
Previous research showed that obesity and diabetes increase lung disease risk, but scientists didn’t fully understand why. This study identifies damaged cells as a key mechanism. The findings align with growing evidence that removing these damaged cells (called senolytic therapy) may help treat various age-related diseases. This is the first study to specifically link this approach to metabolic-related lung disease.
The human portion of the study included only 15 patients, which is a small number. The research doesn’t prove that MitoTam works in humans—it only shows it works in mice and that surgery produces similar cellular changes in humans. Long-term effects are unknown. The study doesn’t compare MitoTam directly to other treatments or to a placebo group in humans. More research is needed before this drug could be used in clinical practice.
The Bottom Line
This research is promising but preliminary. People with obesity or diabetes should not expect MitoTam as a treatment yet—it’s still in early research stages. Current evidence-based recommendations remain: maintain a healthy weight, manage blood sugar, and follow your doctor’s advice. If you have lung disease or metabolic problems, discuss this research with your healthcare provider. Confidence level: Low for MitoTam (animal studies only); High for weight loss and metabolic control (well-established benefits).
This research is most relevant to people with obesity, type 2 diabetes, or early-stage lung disease. Healthcare providers treating metabolic and lung diseases should follow this research. People considering weight-loss surgery may find this information encouraging, as it explains one mechanism by which surgery improves health. This research is less immediately relevant to people with normal weight or well-controlled metabolic health.
In the mice studied, improvements appeared relatively quickly after MitoTam treatment. In humans undergoing weight-loss surgery, metabolic improvements typically appear within weeks to months, with continued benefits over years. If MitoTam enters human trials, benefits would likely take months to become apparent. Full lung healing could take longer.
Frequently Asked Questions
Can obesity cause lung disease?
Yes. A 2026 study found that obesity increases lung scarring risk through damaged cell accumulation. Obesity triggers chronic inflammation and oxidative stress that damage lung tissue. Weight loss and metabolic control can reduce this risk.
What is MitoTam and when will it be available?
MitoTam is an experimental drug that targets damaged cells in the body. It’s currently in early research stages—tested only in mice and not yet approved for human use. Human clinical trials would need to occur before it becomes available as a treatment.
Does weight-loss surgery help lung disease?
Research suggests yes. A 2026 study of 15 patients found that weight-loss surgery reduced harmful proteins linked to lung scarring and improved metabolic markers. However, surgery carries risks and should only be considered under medical guidance.
What are senescent cells and why do they matter?
Senescent cells are old, damaged cells that stop dividing but don’t die. They accumulate with age and in obesity, releasing harmful proteins that trigger inflammation and scarring. Removing them may prevent disease.
Should I try to remove senescent cells from my body?
Currently, no proven human treatments exist for removing senescent cells outside of weight loss and healthy aging practices. MitoTam is experimental. Focus on evidence-based approaches: maintain healthy weight, exercise, manage blood sugar, and follow your doctor’s recommendations.
Want to Apply This Research?
- Track body weight weekly and blood sugar levels (if diabetic) daily. Monitor lung function if you have respiratory symptoms by noting shortness of breath during normal activities on a 1-10 scale. Record these metrics in your health app to identify trends over time.
- If you have obesity or diabetes, use the app to set and track weight-loss goals and exercise minutes. Log meals to monitor calorie intake and carbohydrate consumption. Set reminders for medication adherence and doctor appointments. Share progress reports with your healthcare provider.
- Establish a baseline of current weight, blood sugar (if applicable), and respiratory symptoms. Check these metrics monthly and review trends quarterly. If pursuing weight loss, track the rate of change (aim for 1-2 pounds per week). Share data with your doctor to adjust treatment plans as needed.
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. MitoTam is an experimental drug not approved for human use. People with obesity, diabetes, or lung disease should consult their healthcare provider before making any treatment decisions. Weight-loss surgery carries significant risks and should only be considered under medical supervision. Do not delay or avoid standard medical care based on this information.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.